Cartilage-hair hypoplasia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:175OMIM:250460Q78.8
Who is this for?
Show terms as
16Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Cartilage-hair hypoplasia (CHH), also known as metaphyseal chondrodysplasia, McKusick type, is a rare autosomal recessive skeletal dysplasia caused by mutations in the RMRP gene, which encodes the RNA component of the mitochondrial RNA-processing endoribonuclease complex. The condition was first described in the Old Order Amish population but occurs worldwide. CHH is characterized by short-limbed short stature (dwarfism) that is evident at birth, with disproportionately short limbs relative to the trunk. The skeletal abnormalities result from defective cartilage growth, particularly at the metaphyses of long bones. Fine, sparse, light-colored hair with reduced diameter is a hallmark feature, though hair findings can vary in severity. Beyond the skeletal and hair manifestations, CHH affects multiple body systems. A significant proportion of patients have immune deficiency ranging from mild to severe combined immunodeficiency, which increases susceptibility to infections, particularly viral infections such as varicella. Affected individuals also have an increased risk of malignancies, especially non-Hodgkin lymphoma and other cancers, as well as basal cell carcinoma. Additional features may include macrocytic anemia or other hematologic abnormalities, Hirschsprung disease, and impaired spermatogenesis in males. Joint hypermobility, particularly of the hands, and ligamentous laxity are common. Treatment of CHH is largely supportive and symptom-directed. Growth hormone therapy has been used with limited benefit. For patients with severe combined immunodeficiency, hematopoietic stem cell transplantation (HSCT) may be considered and can correct the immunological defects. Immunoglobulin replacement therapy may be used for antibody deficiency. Regular monitoring for malignancies and infections is essential. Orthopedic interventions may be needed for skeletal complications such as leg bowing. Prognosis varies widely depending on the severity of immune dysfunction, with some patients having a near-normal lifespan while others face life-threatening complications from infections or malignancy.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal diaphysis morphologyHP:0000940Limited elbow extensionHP:0001377Abnormality of the pancreasHP:0001732Tracheal stenosisHP:0002777
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Cartilage-hair hypoplasia.

View clinical trials →

No actively recruiting trials found for Cartilage-hair hypoplasia at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Cartilage-hair hypoplasia community →

Specialists

16 foundView all specialists →
HK
Hirokazu Kanegane
Specialist
1 Cartilage-hair hypoplasia publication
MT
Mervi Taskinen
Specialist
2 Cartilage-hair hypoplasia publications
DT
Dan Tomomasa
Specialist
1 Cartilage-hair hypoplasia publication
TM
Tomohiro Morio
Specialist
1 Cartilage-hair hypoplasia publication
NL
Natalia Lewandowska
Specialist
1 Cartilage-hair hypoplasia publication
OM
Outi Mäkitie
Specialist
7 Cartilage-hair hypoplasia publications
SV
Svetlana Vakkilainen
Specialist
6 Cartilage-hair hypoplasia publications
HA
Heidi Arponen
Specialist
3 Cartilage-hair hypoplasia publications
TS
Takeshi Sato
Specialist
2 Cartilage-hair hypoplasia publications
TH
Tomonobu Hasegawa
Specialist
2 Cartilage-hair hypoplasia publications
JR
Jaana Rautava
Specialist
2 Cartilage-hair hypoplasia publications
IA
Inês Alves
Specialist
2 Cartilage-hair hypoplasia publications
PK
Paula Klemetti
Specialist
2 Cartilage-hair hypoplasia publications
CC
Catarina Portela Carvalho
Specialist
2 Cartilage-hair hypoplasia publications
LG
Luís Guedes-Martins
Specialist
2 Cartilage-hair hypoplasia publications
OM
Outi Mäkitie
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Cartilage-hair hypoplasia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Cartilage-hair hypoplasiaForum →

No community posts yet. Be the first to share your experience with Cartilage-hair hypoplasia.

Start the conversation →

Latest news about Cartilage-hair hypoplasia

No recent news articles for Cartilage-hair hypoplasia.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Cartilage-hair hypoplasia

What is Cartilage-hair hypoplasia?

Cartilage-hair hypoplasia (CHH), also known as metaphyseal chondrodysplasia, McKusick type, is a rare autosomal recessive skeletal dysplasia caused by mutations in the RMRP gene, which encodes the RNA component of the mitochondrial RNA-processing endoribonuclease complex. The condition was first described in the Old Order Amish population but occurs worldwide. CHH is characterized by short-limbed short stature (dwarfism) that is evident at birth, with disproportionately short limbs relative to the trunk. The skeletal abnormalities result from defective cartilage growth, particularly at the met

How is Cartilage-hair hypoplasia inherited?

Cartilage-hair hypoplasia follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Cartilage-hair hypoplasia typically begin?

Typical onset of Cartilage-hair hypoplasia is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Cartilage-hair hypoplasia?

16 specialists and care centers treating Cartilage-hair hypoplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.